Pharma and BioTech Daily
Pharma & Biotech Daily is a short, AI-generated, human-supervised briefing on what’s important in pharma and biotech.
Each weekday we condense key news on pipelines, deals, regulation and strategy into a quick audio update for people who build, run and invest in life sciences.
Produced by OWITH.ai, a boutique AI & data studio.
Sponsor the show: https://sponsor.owith.ai
Pharma and BioTech Daily
Latest Episodes
FDA GLP-1 Vision Warning, Compass Psilocybin NDA | Pharma and Biotech Daily
The FDA adds a possible NAION vision loss risk to the labels of all GLP-1 drugs, and Compass Pathways completes its psilocybin application for treatment resistant depression. Plus AstraZeneca buys Omniose, Abeona licenses a Phase three ready esoph...
Beam Base Editing Sickle Cell Win, FDA Approves Pimjetmi | Pharma and Biotech Daily
Beam Therapeutics' base editing therapy risto-cel meets its primary endpoint in the pivotal BEACON sickle cell study, and the FDA approves Pimjetmi, pimicotinib, from Abbisko and Merck KGaA for tenosynovial giant cell tumor. Also: BIO's BioAdvance...
Vir Hepatitis Delta Phase 3 Win, argenx $1.15B Peptide Deal | Pharma and Biotech Daily
Vir Biotechnology reports a pivotal Phase 3 win in chronic hepatitis delta, and argenx agrees to buy Unnatural Products for up to 1.15 billion dollars to add oral macrocyclic peptides. Also: TG Therapeutics raises Briumvi guidance, Xenon's azetuka...
Lp(a)HORIZON Fails at AHA, FDA's Big November | Pharma and Biotech Daily
Full Lp(a)HORIZON results at AHA show Novartis' pelacarsen cut Lp(a) by 78 percent with no cardiovascular benefit, as the FDA heads into a crowded month of decisions on ivonescimab, deramiocel and povetacicept. Also: Mineralys' lorundrostat holds ...
Zealand Pharma & Generate Biomedicines' $1.2B AI Deal | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of exciting advancements and strategic shifts reshaping the landscape of drug develo...